Acrivon Therapeutics, Inc. (ACRV) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-21

Key Insights

Chief Legal Officer Mary Miller disposed of 558 shares at $1.78 per share on April 17, 2026, resulting from mandatory tax withholding on vesting restricted stock units rather than a discretionary sale.
Miller retains 33,121 shares of direct beneficial ownership following the transaction, indicating continued material stake in the company despite the stock price at $1.78.
The transaction represents routine equity compensation vesting activity typical for executive officers, with no indication of loss of confidence in the company or strategic shift in insider positioning.

Want the newest filings?

This analysis covers the filing from 2026-04-21. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-21

Insider Mary Miller, the Chief Legal Officer, disposed of 659 shares of Acrivon Therapeutics (ACRV) at $1.98 per share to cover tax withholding requirements on vested restricted stock units.
The reported transaction reduces Miller's direct beneficial ownership to 33,896 shares, indicating she continues to hold a significant stake in the company.
Insider transactions, especially those related to stock awards and tax obligations, can provide insight into management's confidence and alignment with shareholders.

Filed: 2026-01-16

Adam D. Levy, the Chief Financial Officer of Acrivon Therapeutics, Inc. (ACRV), purchased 8,832 shares of the company's common stock on January 14, 2026 at a weighted average price of $1.6983 per share.
The insider purchase represents a direct ownership increase of 72% for Levy, who now beneficially owns a total of 20,983 shares of ACRV.
Insider buying can be a positive signal to investors, as it suggests the CFO's confidence in the company's prospects and potential future appreciation of the stock price.

Filed: 2026-01-16

The reporting person, Peter Blume-Jensen, President and CEO of Acrivon Therapeutics, purchased 49,000 shares of the company's common stock at an average price of $1.676 per share, increasing his direct beneficial ownership to 2,095,771 shares.
Kristina Masson, the EVP of Business Operations and Blume-Jensen's spouse, also holds an indirect beneficial ownership of 314,706 shares of Acrivon Therapeutics.
The Form 4 filing indicates that the insider transactions were made pursuant to a pre-arranged trading plan, suggesting a degree of confidence in the company's long-term prospects.

Filed: 2026-01-15

Eric Devroe, the Chief Operating Officer of Acrivon Therapeutics, Inc., has purchased 10,000 shares of the company's common stock at an average price of $1.7218 per share, indicating his confidence in the company's future prospects.
This insider buying activity represents a direct ownership increase of 15.3% for Devroe, suggesting he believes the current stock price presents an attractive investment opportunity.
The transaction was executed through multiple trades within a price range, indicating Devroe's diligence in securing the best possible execution for his purchase.

Other reports for Acrivon Therapeutics, Inc.

Annual Report Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.